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ABSTRACT:
High-mobility group A1 (HMGA1) proteins are architectural chromatinic proteins, 
abundantly expressed during embryogenesis and in most cancer tissues, but expressed 
at low levels or absent in normal adult tissues. Several studies have demonstrated 
that HMGA1 proteins play a causal role in neoplastic cell transformation. The aim of 
this study was to investigate the role of these proteins in the control of cancer stem 
cells (CSCs), which have emerged as a preferred target in cancer therapy, because 
of their role in cancer recurrence. We observed that HMGA1 is overexpressed in 
colon tumour stem cell (CTSC) lines compared to normal and colon cancer tissues. 
We demonstrated that HMGA1 silencing in CTSCs increases stem cell quiescence and 
reduces self-renewal and sphere-forming efficiency (SFE). The latter, together with 
the upregulation and asymmetric distribution of NUMB, is indicative of the recovery 
of an asymmetric division pattern, typical of normal stem cells. We further found 
that HMGA1 transcriptionally regulates p53, which is known to control the balance 
between symmetric and asymmetric divisions in CSCs. Therefore, our data indicate a 
critical role for HMGA1 in regulating both self-renewal and the symmetric/asymmetric 
division ratio in CSCs, suggesting that blocking HMGA1 function may be an effective 
anti-cancer therapy.
INTRODUCTION
Cancer arises from a small set of stem cells, or 
tumour-initiating cells, that differ from normal stem 
cells in their deregulated self-renewal and differentiation 
programs (1). Chemotherapy improves the 5-year survival 
of adult cancer patients by only 2.3% in Australia and 
2.1% in the USA (2). Surrogate end point parameters such 
as ‘progression-free survival,’ ‘disease-free survival,’ or 
‘recurrence-free survival’ reflect the temporary pause in 
the progression of the disease, seldom lasting more than 
a few months. Subsequently, the cancer typically returns 
with even more aggressive characteristics due to a few 
tumour-founding cells (the cancer stem cells or CSCs), 
which, because of their intrinsic chemoresistance, are 
spared and “naturally selected” by the routinely used anti-
cancer drugs. This common trend makes the identification 
of CSC-specific targets and tightly related CSC-specific 
drugs necessary for the development of new effective anti-
cancer therapies.  
The High-Mobility Group A (HMGA) family 
includes three proteins: HMGA1a, HMGA1b, and 
HMGA2. These proteins are encoded by two distinct 
genes; the HMGA1a and HMGA1b proteins are products 
of the same gene through alternative splicing (3). The 
HMGA proteins bind the minor groove of AT-rich DNA 
sequences through their DNA binding domains, the 
so-called “AT-hooks.” HMGA proteins do not exhibit 
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transcriptional activity per se, but they regulate the activity 
of several genes by interacting with the transcription 
machinery and altering the chromatin structure (4). The 
levels of HMGA proteins are low or absent in normal 
cells and adult tissues but are elevated in many tumours, 
neoplastically transformed cells, and embryonic cells (4). 
Their overexpression is largely associated with a highly 
malignant phenotype and also represents a poor prognostic 
marker, as HMGA overexpression often correlates 
with the presence of metastasis and reduced survival 
(5). Moreover, several studies indicate a causal role for 
HMGA gene expression in the process of carcinogenesis. 
Indeed, it has been reported that the blockage of their 
expression prevents thyroid cell transformation and 
promotes the death of malignant cells (6-7). Transgenic 
mice overexpressing either HMGA1 or HMGA2 develop 
uterine tumours, haematopoietic tumours, and pituitary 
adenomas (8-11).
The observation of HMGA1 upregulation in colon 
cancer dates back to 1996, when our group detected the 
HMGA1 proteins, previously called HMGI(Y), in human 
colorectal cancer cell lines and tissues but not in normal 
intestinal mucosa (12). Subsequently, we reported that 
HMGA1 protein expression was associated with the early 
stages of the neoplastic transformation of colon cells but 
only rarely with colon cell hyperproliferation (13), closely 
correlating with the degree of cellular atypia in adenomas. 
Very recently, Belton and colleagues (14) reported that 
HMGA1 overexpression induces cell proliferation and 
polyp formation in the intestines of HMGA1 transgenic 
mice and leads to metastatic progression and stem cell-
like properties in colon cancer cells (14), suggesting that 
HMGA1 is a key regulator both in metastatic progression 
and in the maintenance of a stem cell-like state (14). 
Therefore, the aim of our study was to investigate the 
role of the HMGA proteins in colon cancer stem cells by 
silencing their expression. 
Here, we report that HMGA1 silencing dramatically 
affects the survival of colon tumour stem cells and shifts 
stem cell division to an asymmetric pattern. The ability of 
HMGA1 to negatively regulate p53 promoter activity at 
the transcriptional level at least partially accounts for the 
effects induced by its inhibition on CTSCs. 
RESULTS
HMGA1 is overexpressed in CTSCs and in the 
CD133+ sub-population
We first analysed HMGA1 expression by western 
blot in normal colonic mucosa (NM), colon cancer, colon 
cancer cell lines and CTSC lines. As shown in Figure 
1A, HMGA1 was undetectable in NM, whereas it was 
expressed in colon cancer (Tumour#3), in 3 colon cancer 
cell lines (SW48, SW480 and CACO2), and CTSCs 
(CTSC#18 and CTSC#1.1), which exhibited the highest 
HMGA1 expression. Interestingly, when CTSCs were 
stained for the cancer stem cell marker CD133 and then 
sorted, HMGA1 expression was enriched in CD133+ 
cells (Figure 1B). These data indicate that HMGA1 is 
overexpressed in CTSCs and is more abundant in stem 
cells than in precursors. 
HMGA1 knockdown impairs CTSC growth and 
induces apoptosis
To understand the role of HMGA1 in CTSC, 
we silenced HMGA1 expression in the CTSC#18 cell 
line, using a short hairpin interfering construct (see the 
Materials and Methods section), leading to an HMGA1 
knockdown efficiency of approximately 50%-80% 
in stable transfectants (Figure 2A). Growth curves 
performed on single-cell suspensions demonstrated that 
the knockdown of HMGA1 significantly reduced CTSC 
Figure 1: HMGA1 expression in CTSCs. A) Western blot for HMGA1 in normal colonic mucosa (NM), colon cancer sample 
Tumour#3, colon tumour-derived cell lines (SW48, SW480, GEO, and CACO3), and colon tumour stem cells (CTSC#18 and CTSC#1.1). 
B) Western blot for HMGA1 in unsorted CTSC#18 and sorted CD133+ and CD133- cells. GAPDH was used as a loading control. 
Oncotarget3236www.impactjournals.com/oncotarget
proliferation (p < 0.05) (Figure 2B). The analysis of cell 
cycle progression, performed by flow cytometric analysis, 
demonstrated that HMGA1 knockdown reproducibly 
altered cell cycle progression, inducing a mean increase 
of 5% in the G1 phase population and a concomitant mean 
reduction of 4% in the S phase (Figure 2C). As expected, 
HMGA1 knockdown reduced the expression of stem cell/
pluripotency genes, such as SOX2 and NANOG (Figure 
2D).
Because the alteration of the cell cycle only partially 
accounts for the reduction in CTSC proliferation induced 
by HMGA1 knockdown, we investigated apoptotic cell 
death. TUNEL (terminal deoxynucleotidyl transferase 
dUTP nick-end labeling) assays performed on stable 
transfectants exhibited a 7-fold increase in apoptotic cell 
numbers in CTSC_shA1 with respect to control cells 
(Figures 3A and B). These data suggest that, as in other 
cell systems (4), HMGA1 plays a key role in CTSC 
proliferation by affecting cell cycle progression and 
apoptosis. 
HMGA1 silencing impairs CTSC self-renewal and 
sphere-forming efficiency in serial passages
CTSCs, as other types of cancer stem cells, are 
characterised by their ability to form spheres in suspension 
cultures (15) or in a semisolid medium. The number of 
spheres reflects the quantity of cells capable of in vitro 
self-renewal, whereas the number of cells per sphere 
measures the self-renewal capacity of each sphere-
generating cell (16). Therefore, we assayed the ability of 
cells to form spheres in methylcellulose-based medium. 
A dramatic reduction in the number of spheres (Figure 
4A) and in their diameter (Figure 4B) was observed in 
CTSC_shA1 cells compared with control CTSC_ctrl, thus 
indicating that HMGA1-interference affects CTSC self-
renewal. 
CSCs are known to differ from normal stem cells 
both in their deregulated self-renewal and cell division 
pattern, and an evaluation of their sphere-formation 
efficiency (SFE) in serial passages allows the assessment 
of the rate at which CSCs divide symmetrically (16-
17). As shown in Figure 4C, the SFE of CTSC_shA1 
cells decreased at every passage, whereas the number of 
spheres derived from parental (not shown) or CTSC_ctrl 
cells increased progressively. Interestingly, previous 
studies have demonstrated that the knock-out of p53 
leads to increases in SFE and the symmetric division of 
mammary stem cells in serial passages, whereas the p53 
stabiliser Nutlin-3 is able to reduce the SFE of ErbB2 
mammary stem cells in serial passages (18). Consistent 
with these studies, we observed that the treatment of 
parental CTSC#18 with 5 µM Nutlin-3 was able to 
maintain the SFE constant over subsequent passages 
Figure 2: HMGA1 knockdown affects the proliferation and cell cycle of CTSCs. A) Western blots for HMGA1 in untransfected, 
scramble-transfected (CTSC_ctrl) and HMGA1-knockdown (CTSC_shA1) cells. GAPDH is used as a loading control. B) Growth curve 
of stable scramble (CTSC_ctrl) and HMGA1-knockdown (CTSC_shA1) CTSCs. Data are the mean value ± SD of one representative 
experiment, performed in quadruplicate (*, p < 0.05, Mann-Whitney U-test). C) Histogram of the FACS analyses in CTSC_ctrl and CTSC_
shA1 cells. Data are the mean value ± SD of 3 independent experiments. D) Relative expression of SOX2 and NANOG gene expression 
in CTSC_ctrl and CTCS_shA1 cells, as determined by qRT-PCR. The expression level of each gene was normalized to the G6PD gene 
expression (*, p < 0.05; **, p < 1.01. Mann-Whitney U-test).
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Figure 3: HMGA1 knockdown effects on apoptosis in CTSCs. A) Fluorescence micrographs of TUNEL assays performed on 
non-transfected CTSCs (CTSC), CTSC_ctrl and CTSC_shA1 cells, double-stained with Hoechst dye (left) to identify total nuclei and with 
TMR red UTP (right) to identify apoptotic, TUNEL-positive cells. B) Bar chart representation of the number of TUNEL-positive cells per 
100 Hoechst-positive nuclei in the samples shown in A. Each bar represents the mean ± SD of 10 arbitrary fields. An asterisk indicates the 
significance of the difference between CTSC_shA1 and CTSC_ctrl (*, p = 0.0014; Kruskal-Wallis test followed by Dunn’s post-hoc test).
Figure 4: Effects of HMGA1 knockdown on the sphere-formation ability of CTSCs. A) The diagram represents the average 
number of spheres in the methylcellulose-based medium after 7 days. Spheres with diameters > 70 µm were counted in each of 10 
representative fields. Triple asterisks indicate the significance of the difference in the number of spheres formed by CSC_ctrl and CTSC_
shA1 cells (***, p < 0.001; Mann-Whitney U-test). B) Diagram showing the sphere diameter distribution in CTSC_ctrl and CTSC_shA1 
cells. Each bar represents the mean ± SD diameter found in 10 representative fields. (***, p < 0.001; Mann-Whitney U-test). C) Diagram 
showing the sphere-formation efficiency (SFE) ± SD in scramble- and HMGA1-knockdown CTSCs in serial passages (from F0 to F3). The 
spheres were disaggregated every 10 days. SFE is measured as the percentage of the number of spheres per plated cell at every passage. 
The data represent the results of two independent experiments. D) Sphere-formation efficiency (SFE) in parental CTSC#18 cells treated 
with DMSO or Nutlin-3 (5 µM) in serial passages (from F0 to F3). Spheres were disaggregated every 7 days. The data represent the mean 
value ± SD of two independent experiments. 
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(Figure 4D), similar to what was observed for CTSC_
shA1 cells. Conversely, SFE increased in DMSO-treated 
cells (Figure 4D). Therefore, these results indicate that 
HMGA1 silencing not only restores the ability to divide 
asymmetrically but also exhibits a more dramatic effect 
than p53 stabilisation alone. 
HMGA1 silencing induces quiescence and the 
asymmetric distribution of Numb in CSCs 
Long-term label retention of PKH26 dye is 
frequently used as an indicator of normal stem cell 
quiescence (19). Indeed, rapidly and symmetrically 
dividing CSCs tend to quickly lose PKH26 (18), which 
irreversibly binds to the lipid bilayers on cell membranes 
and is equally distributed among daughter cells during 
each cell division. Conversely, normal quiescent stem cells 
divide asymmetrically in one proliferating progenitor and 
one self-renewing PKH26-retaining quiescent stem cell. 
Therefore, we stained CTSC_shA1 and control CTSC_ctrl 
cells with PKH26 and performed FACS analyses after 
10 days. As shown in Figure 5A and B, knockdown of 
HMGA1 expression led to a drastic increase in PKH26bright 
cells (1.5 % in CTSC_ctrl cells versus 4.8 % in CTSC_
shA1 cells), suggesting that the reduction in HMGA1 
expression confers properties of quiescence to the stem 
cell compartment. Interestingly, very similar results were 
obtained when HMGA1-knockdown brain tumour stem 
cells (BTSCs) were stained with PKH26 (Colamaio et al., 
manuscript in preparation). 
Asymmetric cell division can be demonstrated by 
the asymmetric partitioning of the cell fate determinant 
Numb (19). During asymmetric cell division, the part of 
the cell that inherits high levels of Numb will undergo 
differentiation, whereas the part that inherits low levels 
will produce a stem cell (20); conversely, in symmetrically 
dividing CSCs, Numb is expressed at lower levels and is 
Figure 5: HMGA1 knockdown induces stem cell quiescence and asymmetric Numb distribution. A) FACS plots of double-
coloured (PKH26-phycoerythrin [PE] and fluorescein isothiocyanate [FITC-A]) CTSC_ctrl and CTSC_shA1 cells (one representative 
experiment). The left-most panel shows cells non-stained with PKH26, gated on physical parameters (forward scatter [FSC] and side scatter 
[SSC]) to exclude most of the debris and dead cells. B) Mean percentage of PKH26bright cells in CTSC_ctrl and CTSC_shA1 populations, 
after 10 days from staining. Each bar represents the mean ± SD of 5 independent experiments (*, p < 0,05; Mann-Whitney U-test).C) Western 
blot for Numb in non-transfected, CTSC_ctrl and CTSC_shA1 cells. GAPDH was used as a loading control D) Immunofluorescence for 
Numb in CTSC_ctrl (left) and CTSC_shA1 (right) cells. The nuclei are stained in blue with DAPI. Arrows denote the crescent-shaped 
Numb distribution, whereas asterisks indicate nuclear-localised Numb. The histogram shows the percentage of cells with crescent-shaped, 
asymmetric Numb distribution, obtained in immunofluorescence analyses, as in C). Data are the mean value ± SD of 7 arbitrary fields for 
each sample. (** , p = 0.0048; Mann-Whitney U-test).
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uniformly distributed in such a way that both daughter 
cells will be equal in terms of Numb expression and 
function (20). 
Therefore, we analysed Numb expression/
distribution in HMGA1-knockdown and control 
cells. Western blot analysis for Numb revealed higher 
levels of Numb in CTSC_shA1 cells with respect 
to untransfected and CTSC_ctrl cells (Figure 5C). 
Moreover, immunofluorescence of the spheres (Figure 5D) 
demonstrated that whereas Numb was distributed almost 
uniformly in the cell cytoplasm of CTSC_ctrl cells, it 
formed an asymmetric punctuate crescent close to the cell 
membrane (Figure 5D, right panel, arrows) in CTSC_shA1 
cells, where it also underwent partial nuclear localisation 
(asterisks). The frequency of Numb crescents increased 
from approximately 6% in control cells, to approximately 
32% in CTSC_shA1 cells (Figure 5E). Together, these 
data demonstrate that HMGA1-silencing restores normal 
stem cell properties in CSCs, such as quiescence and 
asymmetric division.
HMGA1 regulates p53 expression at the 
transcriptional level
Because it has been previously shown that 
an imbalance between asymmetric and symmetric 
division can be determined by loss of the p53 tumour 
suppressor (18), we analysed p53 expression in CTSC_
shA1 cells. Western blots performed on untransfected, 
scramble-transfected, and HMGA1–knockdown CTSCs 
demonstrated that the downregulation of HMGA1 
increased p53 protein expression (Figure 6A, upper panel) 
and was associated with an increase in the p53-regulated 
p21 protein (Figure 6A, middle panel), indicating the 
presence of a functional p53.
Subsequently, to assess the direct action of HMGA1 
on p53 transcription, we evaluated HMGA1 protein 
Figure 6: HMGA1 negatively regulates p53 expression at the transcriptional level. A) Western blot analysis for p53 (upper 
panel) and p21 (middle panel) expression in non-transfected, HMGA1-knockdown, and scramble-transfected cells. GAPDH was used 
as a loading control. B) ChIP assay, detecting the in vivo binding of HMGA1 to the 5 sub-regions in the p53 promoter in CTSC_ctrl and 
CTSC_shA1 extracts. The relative occupancy of the p53 promoter regions by HMGA1 is indicated as vertical bars. GAPDH promoter 
amplicon was used as a negative control C) Luciferase activity of the p53 promoter in HEK293 cells in the presence or absence of an 
HMGA1-expressing vector. The amounts of the HMGA1-expressing vector are indicated. The data are the results of three independent 
experiments performed in duplicate. The relative luciferase activity was normalised with Renilla luciferase and was expressed as the fold 
induction over the activity of the p53 promoter (*, p < 0.05). pGL3-basic activity in the presence or absence of the HMGA1-expressing 
construct was used as a negative control. 
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binding to the p53 promoter in vivo by performing ChIP 
assays. Therefore, CTSC_ctrl and CTSC_shA1 cells 
were cross-linked and immunoprecipitated with anti-
HMGA1 or anti-IgG antibodies. Immunoprecipitation of 
chromatin was then analysed by quantitative PCR, using 
primers spanning 5 different regions of the p53 promoter 
(see the Materials and Methods section). Occupancy 
of the p53 promoter regions II and III by HMGA1 was 
clearly detectable (Figure 6B), whereas no amplification 
was observed in regions I, IV, and V, indicating the 
specificity of the binding to regions II and III (Figure 
6B). Conversely, CTSC_shA1 cells exhibited a negligible 
enrichment for regions II and III (Figure 6B) and no 
enrichment at all for the remaining regions. These results 
indicate that HMGA1 protein binds the p53 promoter 
region in vivo.
Finally, to define the functional importance of 
HMGA1 binding to the p53 promoter, we evaluated the 
activity of the p53 promoter in the presence or absence 
of HMGA1, by performing luciferase assays. Therefore, 
HEK293 cells were transfected with a reporter construct, 
carrying the human p53 promoter (21) or a control 
backbone vector (pGL3-basic) in the presence of an 
HMGA1-expressing construct. As shown in Figure 6C, 
HMGA1 repressed the p53 promoter, and this effect 
was dose-dependent. Consistently, this repressive effect 
was abolished by the pharmacological blocking of the 
HMGA1-DNA interaction with distamycin (not shown), 
a drug known to displace HMGA1 from its AT-rich DNA 
regions (22). Therefore, these results clearly demonstrate 
that HMGA1 transcriptionally regulates p53 expression.
DISCUSSION
CSCs are a distinct subset of cancer cells with the 
ability to self-renew through symmetric division and to 
generate a repertoire of various cell types, thus initiating 
and perpetuating tumour growth. CSCs are often endowed 
with distinctive surface markers, such as CD133, which, 
in colon cancer, in gliomas and other cancers, decorates 
tumour-initiating cells versus cells that are unable to 
initiate tumours in transplantation experiments (23). 
In human cancers, CSCs have been demonstrated to be 
a major cause of cancer treatment resistance, invasion, 
metastasis, and relapse. Thus, eliminating cancer cells 
with stem cell properties is of prime importance for the 
successful treatment of cancer, regardless of the tissue of 
origin.
Recent studies have suggested the critical role of the 
HMGA1 protein as a master regulator in both cancer stem 
cells (14; 24) and normal embryonic stem cells (25; 24). 
Indeed, HMGA1 has recently been shown to reprogram 
somatic cells into pluripotent stem cells by inducing stem 
cell transcriptional networks (26). Moreover, several 
studies have directly or indirectly demonstrated that 
HMGA proteins are tightly associated with stemness and 
play a critical role in the epithelial-mesenchymal transition 
(EMT) (27).
Here, we present data unveiling a central role for 
HMGA1 in CSC self-renewal. First, we demonstrated 
that HMGA1 is enriched in CTSCs compared with colon 
tumours and cancer cell lines and is more abundantly 
expressed in CD133+ cells than in CD133- cells, 
strengthening its association with tumour-initiating cells.
Next, we demonstrated that the knockdown of 
HMGA1 by antisense methodology in colon CSCs 
induces a drastic reduction in cell proliferation due to a 
slight increase in the G1 phase population and a more 
evident increase in apoptosis, consistent with our previous 
findings (7). Moreover, CTSC_shA1 cells regain two 
properties typical of normal adult stem cells: an increased 
percentage (and brightness) of PKH26-positive cells, 
which indicates increased quiescence, and reduced SFE, 
suggestive of the recovery in asymmetric division at the 
expense of symmetric self-renewing division (17). This 
shift in the division modality, which is supported by the 
increase in the asymmetric distribution of NUMB, might 
be of practical clinical relevance because asymmetric 
division plays a tumour-suppressive role (20). Notably, 
we have achieved comparable results, in terms of SFE 
reduction, PKH26 increase and NUMB distribution in 
HMGA1-knockdown BTSCs (Colamaio et al., manuscript 
in preparation), suggesting the critical role of the HMGA1 
protein in the regulation of CSCs of different tissue origin. 
It has been demonstrated that ErbB2 transgenic 
mice harbour CSCs with an increased frequency of self-
renewing divisions, higher replicative potential, and a 
preponderance of symmetric versus asymmetric division, 
highlighted by the symmetric distribution of the cell 
fate determinant Numb, compared with stem cells from 
wild-type mice (18). In these cells, Nutlin 3-mediated 
stabilisation of p53 was able to restore asymmetric 
division (as evidenced by the recovery of the asymmetric 
distribution of Numb) (18). The striking similarity of the 
phenotype obtained in CTSC_shA1 with Nutlin-3 treated 
CSCs and the tight association of HMGA1 and ErbB2 
expression (28) prompted us to investigate the effect of 
HMGA1 interference on the p53-Numb axis. Indeed, we 
demonstrated that in CTSC_shA1 cells, the expression 
levels of both p53 and its downstream target p21cip are 
increased with respect to control cells. Moreover, we found 
that HMGA1 directly binds to a discrete region in the p53 
promoter, and this binding has functional consequences, 
leading to p53 transcriptional downregulation.
It is worth noting that HMGA1 overexpression 
may lead to p53 inactivation by other mechanisms, such 
as through interfering with p53-mediated transcription 
of the p53 effectors BAX and p21 (29), transcriptionally 
activating the p53 inhibitor MDM2, and cytoplasmically 
relocalising its proapoptotic activator HIPK2 (30; 4). 
Therefore, the restoration of p53 function exerted by 
HMGA1 knockdown likely accounts for the effects of 
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HMGA1 silencing on CSC cells. 
However, we cannot exclude the possibility that in 
addition to a p53-mediated mechanism, HMGA1 silencing 
might affect CSCs through other mechanisms. In fact, 
we have demonstrated that whereas the SFE of Nutlin-
3-treated CTSCs remains constant overtime, the SFE of 
HMGA1-knockdown cells progressively decreases in 
serial passages. 
Since it has been shown that NUMB is able 
to interact with and stabilise p53 (31), the increased 
expression of NUMB observed in CTSC_shA1, 
concomitant with nuclear relocalisation of the protein (F. 
Puca, unpublished preliminary results) would also enhance 
the stabilisation of p53. Therefore, taken together, these 
data suggest the existence of an HMGA1-Numb-p53 
axis in which HMGA1 could play a significant role in 
regulating self-renewal either by directly acting on p53 and 
NUMB or by inhibiting their interaction in the nucleus. 
In conclusion, the results presented herein indicate that 
HMGA1 has a specific role in making decisions about 
stem cell fate, and thus, targeting HMGA1 may represent 
a promising CSC-specific anti-cancer strategy.
MATERIALS AND METHODS
Cell cultures and culture conditions
Colon tumour stem cell lines were kindly donated 
by Prof. Ruggero De Maria (Istituto Superiore di Sanità, 
Rome, Italy) and have been described elsewhere, together 
with their culturing conditions (15). Cytokines added to 
the medium included recombinant human FGF-basic and 
EGF (Peprotech, Rocky Hill, NJ). HEK293 cells were 
maintained in DMEM medium containing 10% fetal calf 
serum (Invitrogen).
Colon samples 
Normal and cancerous intestinal mucosa samples 
were kindly provided by Dott. Marina De Rosa (Facoltà 
di Medicina e Chirurgia, University “Federico II”, Naples, 
Italy) and have been described elsewhere (32). 
Quantitative reverse transcription PCR (qRT-
PCR)
Total RNA was reverse transcribed using the 
QuantiTect Reverse Transcription Kit (Qiagen), and 
qRT-PCR was performed by using Power SYBR Green 
PCR Master Mix (Applied Biosystems, Foster City, 
CA, USA) according to manufacturer’s instructions. 
G6PD was used to normalise RNA levels. The 
primers used were as follows: Hsa_HMGA1_Fw:5’-
CAACTCCAGGAAGGAAACCA, Hsa_HMGA1_Rev: 
5’-AGGACTCCTGCGAGATGC; Hsa_G6PD_Fw: 
5’-ACAGAGTGAGCCCTTCTTCAA, and Hsa_G6PD_
Rev: 5’-ATAGGAGTTGCGGGCAAAG; SOX2_Fw: 5’- 
GCACATGAACGGCTGGAGCAACG; SOX2_Rev: 5’-
TGCTGCGAGTAGGACATGCTGTAGG; 
NANOG_Fw: 5’ - CAAAGGCAAACAACCCACTT; 
NANOG_Rev: 5’- TCTGGAACCAGGTCTTCACC. The 
2–∆∆Ct formula was used to calculate the differential gene 
expression.
Immunostaining and cell sorting
For cell sorting, the cells were trypsinised, washed 
twice with PBS, and incubated with anti-human CD133 
(CD133/2 (293C3)-PE, Miltenyi Biotech) for 20 minutes 
at 4°C. After washing twice with PBS, the cells were 
FACS sorted with a FACScan flow cytometer (Becton 
Dickinson, San Jose, CA) interfaced with a Hewlett-
Packard computer (Palo Alto, CA). 
Western blots and antibodies
Total protein extraction, western blotting, and anti-
HMGA1 antibodies have been described elsewhere (33).
The following other antibodies were used: anti-
GAPDH (Santa Cruz Biotechnology, CA, USA) and 
anti-p21 (Cell Signaling Technology, Inc., Danvers, 
MA). Anti-Numb antibodies were obtained from Abcam 
(Cambridge, UK) and were used at 1:5000. Blots were 
visualised using western blotting detection reagents (GE 
Healthcare, Buckinghamshire, UK).
Plasmids
The hairpin RNA interference plasmid for human 
HMGA1 (pLKO.1-HMGA1, TRCN0000018949) and 
the scramble control pLKO.1-Puro plasmid (SHC002) 
were obtained from Sigma-Aldrich. The sequence of 
the short hairpin RNA targeting the human HMGA1 
gene was 5′–CCGGCAACTCCAGGAAGGAAACCAA 
CTCGAGTTGGTTTCCTTCCTGGAGTTGTTTTT–3′, 
(shHMGA1 targets coding region positions 446-466 of 
HMGA1 mRNA transcript variant 2). 
The pGL3-luci vector containing the p53 promoter 
was kindly provided by Prof. David Reisman (Center for 
Colon Cancer Research Tissue Repository, University of 
South Carolina, Columbia) (21).
The pCDNA3.1-HMGA1 expression vector has 
been described previously (25).
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Transfections 
CTSCs were electroporated using the Neon® 
Transfection System (Invitrogen). Cells were trypsinised 
with TrypLE™ Express (GIBCO) and counted; 1 x 106 
cells were subjected to the electric field (1400 V, 20 
msec; 1 pulse). After 48 h, CTSCs transfected with the 
short hairpin-expressing constructs were selected with 
puromycin (2 µg/µl). 
Growth curves and TUNEL assay
Approximately 5 x 103 stably transfected cells were 
plated in 96-well plates. Cells were counted in triplicate 
at daily intervals with a Burker hemocytometer chamber.
A TUNEL assay was performed using the In 
Situ Cell Death Detection kit (Roche) according to 
manufacturer’s instructions.
Flow cytometry
After trypsinisation, the cells were washed in PBS 
and fixed in 70% ethanol. Staining for DNA content 
was performed with 0.1% NP-40, 50 µg/ml propidium 
iodide, and 25 µg/ml ribonuclease A for 20 min. For each 
measurement, 10,000 events were analysed. We used a 
FACScanto II flow cytometer (Becton Dickinson, San 
Jose, CA). Cell cycle data were analysed with the ModFit 
LT 2.0 software (Verity Software) in a semiautomatic 
analysis procedure. Briefly, we manually selected the cell 
population in an FSC versus SSC dot plot and discarded 
debris, and then we gated single cells in a PI-height versus 
PI-area dot plot, excluding all doublets. The MODFIT 
algorithm was used to analyse our files, calculating the 
percentages of cells in each cell cycle phase. 
Sphere formation assays 
Sphere-forming assays in methylcellulose-based 
medium were performed as previously described (34) 
with some modifications. Briefly, medium containing 
0.8% methylcellulose was used instead of liquid medium, 
and other conditions were the same as in liquid medium. 
Three percent methylcellulose was purchased from R&D 
Systems (Minneapolis, USA), and a stock solution was 
made of 2% methylcellulose in DMEM⁄F12. A final 
concentration of 0.8% methylcellulose in DMEM⁄F12 
was used for cell culture. Approximately 2 x 104 cells 
from disaggregated CTSC spheres were resuspended in 
a semisolid medium and plated in 6-well plates. After 7 
days, the spheres were microscopically visualised, and the 
diameters were measured. 
Serial passage experiments were conducted as 
described previously (18) with some modifications. 
Briefly, 5,000 cells from disaggregated CTSC spheres 
were plated on 150-mm poly-HEMA-treated cell culture 
plates. After 10 days, the spheres were disaggregated 
and re-plated at the same density. The sphere-forming 
efficiency (SFE) at each passage was obtained by 
calculating the percentage of the number of spheres 
divided by the number of cells plated. 
PKH staining and flow cytometric analysis
PKH staining was performed as previously 
described (19).
CTSCs were trypsinised, filtered through a 40-μm 
cell strainer, resuspended in PBS (approximately 500,000 
cells/ml), labelled with PKH26 (Sigma, 10−7 M, 5 min), 
washed twice, and plated. 
For the flow cytometric analysis of PKH26-stained 
cells, CTSCs were trypsinised, filtered through a 40-μm 
cell strainer, and resuspended in PBS at a concentration of 
1x106/ml. The cells were subdivided into 5-ml polystyrene 
tubes (Falcon, Becton Dickinson). The BD FACSAria 
cytometer, equipped with four excitation laser lines (633 
nm, 488 nm, 405 nm, and 375 nm) (Becton Dickinson) 
was used for FACS analysis, and the BD FacsDIVA 
software was used for data analysis.
PKH26 staining was evaluated by selecting the 
appropriate cell population according to the following 
gating strategy: (i) cells were first gated on physical 
parameters (forward scatter [FSC] and side scatter [SSC]) 
to exclude most of the debris and dead cells; (ii) doublets 
and aggregates were eliminated using the FSC-area vs. 
FSC-height pattern. We gated 10-15% of the brightest 
PKH26+ cells in a PKH26 versus empty channel dot plot. 
Immunofluorescence
Whole spheres were centrifuged and fixed with 
4% paraformaldehyde, permeabilised, with 0.1% Triton 
X-100 and 3% BSA, and stained with anti-Numb (kindly 
donated by Prof. Salvatore Pece and previously described 
(18), followed by anti-mouse Alexa 488 (Jackson 
ImmunoResearch Europe Ltd., Suffolk, UK) antibodies. 
Confocal analysis was performed with a Leica TCS SP2 
AOBS microscope. 
Luciferase assay
Transfections for luciferase assays were performed 
in HEK293 cells using the Lipofectamine 2000 method 
(Invitrogen S.r.l., S. Giuliano Milanese, MI, Italy). 
Approximately 2 × 105 cells were transiently transfected 
with 200 ng of pGL3-luci vector containing the p53 
promoter (kindly provided by Professor David Reisman, 
Center for Colon Cancer Research Tissue Repository, 
Oncotarget3243www.impactjournals.com/oncotarget
University of South Carolina, Columbia) and with the 
indicated amounts of the pCDNA3.1-HMGA1 expression 
vector or the corresponding empty vector together with 0.5 
μg of Renilla. Various amounts of the pCDNA3.1 plasmid 
were co-transfected to keep the total DNA concentration 
constant. Transfection efficiencies were normalised 
using Renilla luciferase expression assayed with the 
dual luciferase system (Promega Italia, Milan, Italy). All 
transfection experiments were performed in duplicate. 
Chromatin immunoprecipitation
CHIP was performed as described previously (35). 
As a negative control, ChIP experiments were performed 
with isotype-matched preimmune IgG. The promoter 
occupancy was calculated with respect to the input as 
the percentage of anti-A1-immunoprecipitated DNA 
subtracted from the IgG-immunoprecipitated DNA. The 
P53 promoter regions assayed for HMGA1 binding refer 
to the nucleotide sequence previously published (21) and 
are indicated as follows: Region I: nt 401-557; region II: 
nt 538-650; region III: nt 631-751; region IV: nt 767-890; 
and region V: nt 989-1090.
The primers for each region were as follows: 
Prom_hQ_tp53_1_F: 
5’-CAGGCTTCAGACCTGTCTCC
Prom_hQ_tp53_1_R: 
5’-GCTTTCAGTACATGGAAACGTAA
Prom_hQ_tp53_2_F: 
5’-CGTTTCCATGTACTGAAAGCAA
Prom_hQ_tp53_2_R: 
5’-CCCTAACGTTTTCTCCCAGA
Prom_hQ_tp53_3_F: 
5’-TCTGGGAGAAAACGTTAGGG
Prom_hQ_tp53_3_R: 
5’-AAGGGTGGAAGGAAGAAAGC
Prom_hQ_tp53_4_F: 
5’-GCAGGATTCCTCCAAAATGA
Prom_hQ_tp53_4_R: 
5’-GAGGGTGCAGAGTCAGGATT
Prom_hQ_tp53_5_F: 
5’-GTTGATGGGATTGGGGTTTT
Prom_hQ_tp53_5_R: 
5’-AGCTACCTGCTCCCTGGAC
Prom_GAPDH_1F: 
5’-CCCAAAGTCCTCCTGTTTCA
Prom_GAPDH_R: 
5’-GTCTTGAGGCCTGAGTACG
Statistical analysis
Statistical analyses were performed using the 
Kruskal-Wallis test or the Mann-Whitney U-test. If the 
Kruskal-Wallis test was positive (p < 0.05), a pairwise 
comparison of subgroups was performed using Dunn’s 
post-hoc test.
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